Board of Managers

Bernard Lyons, Ph.D.

Dr. Lyons is a senior healthcare executive and medtech industry consultant.  He has over 40 years of experience in the medical device field.  Dr. Lyons was President and Chief Executive Officer at Direct Flow Medical, Inc. from February 2006 until he retired in May 2015.  Prior to Direct Flow, he served as President and CEO of Vasca, Inc. a later stage, privately held medical device company focused on subcutaneous vascular access ports for hemodialysis treatment in patients with end stage renal disease. Previously Dr. Lyons was President and CEO of CardioClasp, Inc. a development stage start-up medical device company focused on the treatment of congestive heart failure.  Dr. Lyons held several senior level positions at Boston Scientific Corporation during his 15 year tenure where he was the Vice President, Sales & Marketing for Interventional Oncology; Vice President, Sales & Marketing of the Meadox Division; Vice President, Corporate Product Development; and President of Boston Scientific’s operations in Japan. Dr. Lyons is a member of the Board of Directors for Minnetronix, Inc. (St. Paul, MN), Vitara Medical, Inc. (Philadelphia, PA) and REVA Medical, Inc. (San Diego, CA).  He was previously a Director at Paramit Corp. (Morgan Hill, CA) and Creganna Medical (Galway, Ireland).  He is a guest lecturer at the Tuck Business School and Thayer School of Engineering at Dartmouth College where he serves on the Board of Directors for Insight Surgical Technologies, LLC and was previously a Director for CairnSurgical, Inc. (Lebanon, NH).  He is also a guest lecturer with the BioInnovate Program at the National University of Ireland, Galway where he previsoulsy held Board and advisory roles with Vetex Medical, LTD and CrannMed, LTD (Galway, Ireland).  Dr. Lyons is currently an Operating Partner with Altaris Capital (New York, NY) and is an Executive in Residence at Partners HealthCare Innovation (Boston, MA) working with Canon USA (Cambridge, MA) as a business advisor.  He was an Instructor in Surgery at Dartmouth Medical School and Adjunct Assistant Professor at the Thayer School of Engineering at Dartmouth College. Dr. Lyons earned his Ph.D. in Cancer Biology from Stanford University School of Medicine and a B.A. from the University of California, Los Angeles.

Bob Stockman

Bob Stockman’s 40-year career in life sciences spans founding and operational roles in six life science companies and over 25 years of M&A transaction experience. He currently serves as Chairman of REVA Medical, a company he founded and led as CEO, and leads the investment committee of a San Francisco based family trust. He led the buyouts of Ioptex, an intraocular lens manufacturer, and two Johnson & Johnson divestitures, “A” Company Orthodontics, Inc. and Critikon Company, LLC, each of which was subsequently acquired. In addition to REVA, he co-founded CentriMed which became the Global Healthcare Exchange, which transacts $30 billion of hospital supplies today. Bob has served on public company boards, most recently, Heartware, Inc. which was acquired by Medtronic and Zeltiq, which was acquired by Allergan. Bob attended Harvard University and earned his MBA at Dartmouth’s Tuck School of Business, where he was an Overseer.

Nick Taylor

Nick’s interest in Reva began when he invested in the 2011 IPO, and intensified with his instrumental role in the design and structure of the various further rounds of financing in 2014 and 2017.  He has been deeply involved in the company’s strategy, and has introduced key investors.  His extensive career in investing began at Goldman Sachs, he currently works as a portfolio manager in event-driven and special situation investing, which he has done since 1996, managing teams within large financial organisations.  Nick co-founded and subsequently ran Modal Capital Partners, an international event-driven captive hedge fund between 1999 and 2008, was head of Asia-Pacific Proprietary trading for Credit-Suisse, founded and ran Senrigan Capital, an Asia based Event-Driven fund, and was a Senior Managing Director and head of International Principal investments for Citadel.  Nick has set up offices in Tokyo, Hong Kong, London, and Bermuda (a reinsurance company, Modal Re).  He is on the Board of Silver Creek Pharmaceuticalsl and Flowers art gallery.  Nick has an M.A. in Philosophy from Cambridge University, and was a student for D.Phil in Philosophy at Balliol College, Oxford. Prior to moving into an investing career he was a college lecturer in Philosophy at St. Catherine’s college Oxford.

Michael Dake, M.D.

Michael D. Dake, MD, is Senior Vice President for the University of Arizona Health Sciences. As head of the academic medical center, he directs strategic integration of undergraduate and graduate education, research, service and clinical activities in the University of Arizona Health Sciences colleges, centers and clinical affiliates.

Dr. Dake is a leading researcher, clinician, teacher, and administrator. He is internationally known for pioneering image-guided therapies and novel approaches in interventional therapy in the fields of vascular imaging, venous thromboembolic disease, aortic aneurysms, and dissection. Dr. Dake made medical history with the implantation of the world’s first thoracic stent-graft in 1992 and his groundbreaking research with CT angiography and stent-grafts has re-written medical and surgery textbooks.

Prior to joining UArizona Health Sciences, he served at Stanford University as Professor of Cardiothoracic Surgery and Director of the Catheterization and Angiography Laboratories at Stanford Medical Center, where he spent much of his career. Previously, he served as Chairman of the Department of Radiology in the Virginia Health System.

He is a graduate of Harvard College and Baylor College of Medicine, where he completed an internship, residency and chief residency in internal medicine. He pursued fellowship training in pulmonary diseases followed by a residency and chief residency in radiology at the University of California San Francisco. He went on to complete subspecialty training in vascular and interventional radiology at UCSF.

As a member of the University of Arizona’s senior executive team, Dr. Dake works collaboratively with teams across UArizona and with Banner Health to build UArizona Health Sciences’ competitiveness in education, clinical care and biomedical research.

Tamara Elias, M.D.

Tamara Elias, M.D. has been avidly involved with healthcare for over 20 years across a wide spectrum of diverse experiences, beginning with medical school, extending into surgical residency, followed by healthcare strategic consulting, private equity investing, corporate strategy and business development, product innovation and P&L, inclusive of board member positions.

Currently, in her role as VP, Global Partnerships & Innovation at Merck, Tamara leads global “non-product” (“around the pill”) commercial partnerships for Human Health with start-ups and established players across the value chain. Her team’s work includes building new journeys to care for patients by partnering with 3rd parties, scouting of relevant partners, execution of win-win contracts and deal structures, partnering with markets to share best practices and scale based on local successes, and external monitoring of key healthcare trends as it affects our business.

Her prior role was with Aetna as VP, Clinical Product Development, owning a $20M P&L, where she focused on optimizing and rationalizing the existing clinical product portfolio for all lines of business. At Becton Dickinson, she was VP, Corporate Strategy and Business Development for the $8B revenue Medical Segment.  In this role, Tamara engineered the creation of the Digital Health Business Unit – from designing the organization to securing funding to hiring the team and getting the approval of the first concept in digital diabetes (now launched). She was a member of the Leadership Team and worked to advance the overall strategic direction and growth for the medical segment, including the $24B acquisition of CR Bard which closed in December 2017.

Tamara joined Becton Dickinson from Essex Woodlands Healthcare Partners, a private equity firm, where she was a Partner and co-led the healthcare services and healthcare IT growth equity practice and assisted with the management of the medical device growth equity portfolio and practice. In over 8 years with the firm, she served on several boards.

Prior to Essex Woodlands, Tamara spent five years as a strategy consultant at McKinsey, where she advised pharmaceutical, diagnostic and device companies in product commercialization and M&A.

Tamara currently serves on the Board of Directors of Avinger (NASDAQ: AVGR), a public medtech company in the PVD space, as Chairman of the Nominating/Governance Committee and a Member of the Audit and Comp Committees, as well as on the board of REVA Medical LLC, also in the PVD space and BehaVR in the mental health arena.

Tamara holds a BA in both Biology and Anthropology from Yale University, obtained her M.D. from The Johns Hopkins School of Medicine, and pursued a general surgery residency at Massachusetts General Hospital.